All In Biotech

Drug Trial Radar · NCT05997576

A Study of TG103 Injection in Non-diabetic Overweight or Obesity

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity

Last checked: Nov 19, 2026Latest source record: Aug 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 675 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

675

Actual

Start

Nov 22, 2023

Primary completion

Feb 17, 2025

Study completion Mar 3, 2025

Sponsor

Sponsor type
Industry
First posted
Aug 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, double-blind, placebo-controlled, parallel phase 3 study to evaluate efficacy, safety, pharmacokinetics characteristics and immunogenicity of TG103 injection, a GLP-1 receptor agonist, for weight management in non-diabetic patients with BMI greater than or equal to 28 kg/m2 or greater than 24 kg/m2 in the presence of comorbidities, in addition to lifestyle intervention (calorie restrict diet and increased physical activity).

Conditions

  • Overweight or Obesity

Interventions

  • TG103 22.5 mgDrug

    Subcutaneous injections with calorie restrict diet and increased physical activity for 52 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.

  • PlaceboDrug

    Subcutaneous injections with calorie restrict diet and increased physical activity for 52 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with weight loss of ≥ 5% at week 40Time frame: From baseline to week 40
  2. Relative percentage change from baseline in body weight at week 40Time frame: From baseline to week 40

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Trials Information Group

    Shijiazhuang, Hebei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.